

Interim report according to article 37x of the German Securities Trading Act (WpHG)

## **MOLOGEN AG invests into pre-clinical studies in the first quarter of 2007**

**Berlin, May 15, 2007** - In the first quarter 2007, the Berlin-based biotech company MOLOGEN has generated EBIT of -1.7 million EUR in the Consolidated Financial Statements prepared in line with IFRS. In the comparison period, EBIT was -0.8 million EUR. Sales of 0.2 million EUR remained at the level of last year. Net income amounted to -1.6 million EUR compared to -0.8 Million EUR in the first quarter 2006.

The earnings development was significantly influenced by increased R&D expenses for late-stage pre-clinical studies with dSLIM in the colon cancer indication and with the cell-based gene therapy against renal cell carcinoma. Meanwhile, pre-clinical activities in both indications were completed for the most part and regulatory preparations for the initiation of clinical studies have been started. MOLOGEN expects that clinical studies relevant of regulatory approval can be resumed in 2007 for both substances.

Liquid funds amounted to 6.6 million EUR at the end of the first quarter 2007. Including all proceeds from the recent capital increase, which were partly paid after the end of the first quarter, liquid funds would have been at around 11 million EUR. In April, the capital increase was entered in the commercial register.

„The first quarter was strongly influenced by major investments into successful, diversified pre-clinical studies” said Prof Burghardt Wittig, Chief Executive Officer of MOLOGEN AG. “With those studies, we have laid a sound basis for the upcoming clinical development of our cancer therapies starting in 2007. I am very confident that we will achieve important regulatory and financial milestones this year. In addition, further activities to advance the commercialization of our cell-based gene therapy are high on our agenda.”

### **About MOLOGEN**

MOLOGEN AG is a listed biopharmaceutical company with headquarters in Berlin (Frankfurt Stock Exchange, Regulated Market, ISIN DE0006637200). On the basis of patented technologies (MIDGE and dSLIM), MOLOGEN develops DNA-based vaccines and therapeutic agents for the prevention and treatment of a wide range of serious illnesses.

### **Disclaimer concerning prognoses**

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all

information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-

looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.

**MOLOGEN AG**

Fabeckstr. 30, 14195 Berlin, Germany

Contact: Joerg Petrass

E-mail: investor@mologen.com

Phone: +49-30-84 17 88-13

Fax: +49-30-84 17 88-50